{"id":5115,"date":"2025-05-05T13:22:02","date_gmt":"2025-05-05T16:22:02","guid":{"rendered":"https:\/\/sbrv.org\/paciente\/?post_type=doenca&#038;p=5115"},"modified":"2025-05-05T15:21:12","modified_gmt":"2025-05-05T18:21:12","slug":"tratamento-dmri-neovascular","status":"publish","type":"doenca","link":"https:\/\/sbrv.org\/paciente\/doencas-retina\/tratamento-dmri-neovascular\/","title":{"rendered":"Tratamento da DMRI Neovascular: O que \u00e9, Sintomas, Diagn\u00f3stico e Tratamentos | SBRV"},"content":{"rendered":"\n<p>A DMRI neovascular, tamb\u00e9m chamada \u201c\u00famida\u201d, \u00e9 a forma mais agressiva da degenera\u00e7\u00e3o macular relacionada \u00e0 idade. Nessa variante, vasos sangu\u00edneos anormais crescem sob a m\u00e1cula, vazando l\u00edquido e sangue que danificam as c\u00e9lulas retinianas. Sem interven\u00e7\u00e3o, pode levar \u00e0 perda r\u00e1pida e significativa da vis\u00e3o central. Felizmente, tratamentos atuais permitem controlar o processo, muitas vezes preservando ou at\u00e9 recuperando parte da acuidade visual\u00b9.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">O QUE \u00c9 O TRATAMENTO DA DMRI NEOVASCULAR?<\/h2>\n\n\n\n<p>O objetivo principal \u00e9 bloquear o crescimento e a permeabilidade dos vasos anormais, reduzindo incha\u00e7o e hemorragias na regi\u00e3o macular. Isso \u00e9 alcan\u00e7ado por:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Inibi\u00e7\u00e3o de VEGF (fator de crescimento endotelial vascular), principal mediador da forma\u00e7\u00e3o de neovasos.<\/li>\n\n\n\n<li>Terapias adicionais como laser ou fotodin\u00e2mica em casos selecionados.<\/li>\n<\/ul>\n\n\n\n<p><strong>Ilustra\u00e7\u00e3o sugerida:<\/strong> corte esquem\u00e1tico da m\u00e1cula mostrando vasos patol\u00f3gicos e \u00e1rea de exsuda\u00e7\u00e3o.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">CAUSAS E FATORES DE RISCO<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Idade avan\u00e7ada (\u226565 anos).<\/li>\n\n\n\n<li>Hist\u00f3rico de DMRI seca em est\u00e1gio intermedi\u00e1rio ou avan\u00e7ado.<\/li>\n\n\n\n<li>Tabagismo e exposi\u00e7\u00e3o solar intensa.<\/li>\n\n\n\n<li>Gene ARMS2\/HTRA1 associado a maior risco de forma \u00famida\u00b2.<\/li>\n\n\n\n<li>Hipertens\u00e3o e aterosclerose \u2013 favorecem fragilidade vascular.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">SINTOMAS<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Vis\u00e3o central emba\u00e7ada ou ondulada (metamorfopsia)<\/li>\n\n\n\n<li>Mancha escura ou cinza no centro do campo visual<\/li>\n\n\n\n<li>Perda s\u00fabita de detalhes finos<\/li>\n\n\n\n<li>Dificuldade para ler e reconhecer rostos<\/li>\n\n\n\n<li>Sensa\u00e7\u00e3o de imagem \u201cdistante\u201d ou afastada<\/li>\n<\/ul>\n\n\n\n<p><strong>Alerta imediato:<\/strong> qualquer altera\u00e7\u00e3o visual aguda deve levar \u00e0 consulta oftalmol\u00f3gica de urg\u00eancia.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">DIAGN\u00d3STICO<\/h2>\n\n\n\n<ol class=\"wp-block-list\">\n<li>Teste de Amsler: identifica distor\u00e7\u00f5es no campo central da vis\u00e3o.<\/li>\n\n\n\n<li>OCT (Tomografia de Coer\u00eancia \u00d3ptica): detecta l\u00edquido dentro das camadas da retina.<\/li>\n\n\n\n<li>Angiofluoresceinografia: contraste revela neovasos e extravasamento de l\u00edquido.<\/li>\n\n\n\n<li>OCT-A (Angio-OCT): mapeia vasos sem necessidade de contraste.<\/li>\n<\/ol>\n\n\n\n<p><strong>Na consulta:<\/strong> exames indolores, dura\u00e7\u00e3o total de 20\u201330 minutos; o m\u00e9dico explicar\u00e1 os achados e plano terap\u00eautico.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">TRATAMENTOS ATUAIS<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\">1. Inje\u00e7\u00f5es Intrav\u00edtreas de Anti-VEGF<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Principais f\u00e1rmacos:<\/strong> bevacizumabe (off-label), ranibizumabe, aflibercepte, faricimabe\u00b3.<\/li>\n\n\n\n<li><strong>Mecanismo:<\/strong> bloqueiam VEGF, reduzem permeabilidade vascular e neovasculariza\u00e7\u00e3o.<\/li>\n\n\n\n<li><strong>Esquema de aplica\u00e7\u00e3o:<\/strong>\n<ul class=\"wp-block-list\">\n<li>Tratamento inicial intensivo: 1 inje\u00e7\u00e3o mensal por 3\u20136 meses.<\/li>\n\n\n\n<li>Manuten\u00e7\u00e3o: conforme resposta \u2013 \u201cpro re nata\u201d (prn) ou \u201ctreat-and-extend\u201d (aumenta intervalo gradual).<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>Efic\u00e1cia:<\/strong> at\u00e9 90 % dos pacientes estabilizam ou melhoram vis\u00e3o ap\u00f3s 2 anos\u2074.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">2. Terapia Fotodin\u00e2mica (TFD)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Indica\u00e7\u00e3o:<\/strong> casos refrat\u00e1rios de pacientes com vasculopatia polipoidal.<\/li>\n\n\n\n<li><strong>Procedimento:<\/strong> verteporfina intravenosa + laser frio que ativa o corante \u2013 seletivamente oblitera a neovasculariza\u00e7\u00e3o.<\/li>\n\n\n\n<li><strong>Recupera\u00e7\u00e3o:<\/strong> leve desconforto ocular tempor\u00e1rio; acompanhamento mensal.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">3. Fotocoagula\u00e7\u00e3o a Laser<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Uso restrito:<\/strong> les\u00f5es extrafoveais sem comprometimento central.<\/li>\n\n\n\n<li><strong>Objetivo:<\/strong> fotocoagula\u00e7\u00e3o de vasos an\u00f4malos.<\/li>\n\n\n\n<li><strong>Desvantagem:<\/strong> risco de criar cicatriz retiniana, destrui\u00e7\u00e3o do tecido sobrejacente com aumento da intensidade da mancha.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">4. Novas Perspectivas<\/h3>\n\n\n\n<p>Diversos estudos est\u00e3o em andamento que t\u00eam por finalidade avaliar a utiliza\u00e7\u00e3o de novas medica\u00e7\u00f5es e dispositivos de libera\u00e7\u00e3o lenta de medicamentos.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">PROGN\u00d3STICO<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Resposta ao anti-VEGF:<\/strong> maioria estabiliza vis\u00e3o; at\u00e9 40 % melhoram \u22653 linhas de acuidade em 1 ano\u2075.<\/li>\n\n\n\n<li><strong>Fatores progn\u00f3sticos favor\u00e1veis:<\/strong> in\u00edcio precoce, boa ader\u00eancia, aus\u00eancia de cicatrizes pr\u00e9vias.<\/li>\n\n\n\n<li><strong>Risco de recorr\u00eancia:<\/strong> tratamento cont\u00ednuo pode ser necess\u00e1rio por anos.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">PREVEN\u00c7\u00c3O E CUIDADOS<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Monitoramento domiciliar com teste de Amsler.<\/li>\n\n\n\n<li>Consulta oftalmol\u00f3gica ao primeiro sinal de metamorfopsia.<\/li>\n\n\n\n<li>Controle de comorbidades sist\u00eamicas: press\u00e3o arterial e colesterol.<\/li>\n\n\n\n<li>Prote\u00e7\u00e3o UV e cessa\u00e7\u00e3o do tabagismo.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">PERGUNTAS FREQUENTES<\/h2>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>As inje\u00e7\u00f5es doem?<\/strong><br>\u2013 Pequeno desconforto; procedimento r\u00e1pido sob anestesia local.<\/li>\n\n\n\n<li><strong>Quantas inje\u00e7\u00f5es vou precisar?<\/strong><br>\u2013 Varia; no m\u00ednimo 3 mensais, depois intervalo conforme resposta.<\/li>\n\n\n\n<li><strong>Posso parar o tratamento se melhorar?<\/strong><br>\u2013 S\u00f3 com aval m\u00e9dico; interrup\u00e7\u00e3o abrupta pode causar reca\u00edda.<\/li>\n\n\n\n<li><strong>Existe risco de complica\u00e7\u00f5es graves?<\/strong><br>\u2013 Raro; podem ocorrer infec\u00e7\u00e3o ou aumento de press\u00e3o intraocular.<\/li>\n\n\n\n<li><strong>O tratamento funciona em todos?<\/strong><br>\u2013 A maioria responde bem, mas cerca de 10\u201315 % t\u00eam resposta sub\u00f3tima.<\/li>\n<\/ol>\n\n\n\n<h2 class=\"wp-block-heading\">REFER\u00caNCIAS BIBLIOGR\u00c1FICAS<\/h2>\n\n\n\n<ol class=\"wp-block-list\">\n<li>Brown DM, et al. Ranibizumab versus verteporfin for neovascular AMD. N Engl J Med. 2006;355(14):1432\u20131444.<\/li>\n\n\n\n<li>de Jong PTVM, et al. Genetics of AMD: the how and why. Prog Retin Eye Res. 2017;56:133\u2013159.<\/li>\n\n\n\n<li>Rosenfeld PJ, et al. Anti-VEGF for neovascular AMD: 2-year results. Ophthalmology. 2011;118(2):120\u2013131.<\/li>\n\n\n\n<li>Schmidt-Erfurth U, et al. Treat-and-extend dosing in neovascular AMD. Retina. 2015;35(10):1921\u20131932.<\/li>\n\n\n\n<li>Heier JS, et al. Efficacy of aflibercept in neovascular AMD. Ophthalmology. 2012;119(12):2537\u20132548.<\/li>\n<\/ol>\n","protected":false},"template":"","class_list":["post-5115","doenca","type-doenca","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Tratamento da DMRI Neovascular: O que \u00e9, Sintomas, Diagn\u00f3stico e Tratamentos | SBRV - SBRV - \u00c1rea do Paciente<\/title>\n<meta name=\"description\" content=\"Conhe\u00e7a as op\u00e7\u00f5es de tratamento para DMRI neovascular (\u00famida) e como proteger sua vis\u00e3o. Informa\u00e7\u00e3o confi\u00e1vel da SBRV para pacientes e familiares.\u201d\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/sbrv.org\/paciente\/doencas-retina\/tratamento-dmri-neovascular\/\" \/>\n<meta property=\"og:locale\" content=\"pt_BR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tratamento da DMRI Neovascular: O que \u00e9, Sintomas, Diagn\u00f3stico e Tratamentos | SBRV - SBRV - \u00c1rea do Paciente\" \/>\n<meta property=\"og:description\" content=\"Conhe\u00e7a as op\u00e7\u00f5es de tratamento para DMRI neovascular (\u00famida) e como proteger sua vis\u00e3o. Informa\u00e7\u00e3o confi\u00e1vel da SBRV para pacientes e familiares.\u201d\" \/>\n<meta property=\"og:url\" content=\"https:\/\/sbrv.org\/paciente\/doencas-retina\/tratamento-dmri-neovascular\/\" \/>\n<meta property=\"og:site_name\" content=\"SBRV - \u00c1rea do Paciente\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/pt-br.facebook.com\/sbrv.retina\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-05T18:21:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/sbrv.org\/paciente\/wp-content\/uploads\/sites\/3\/2024\/12\/imagem-yoast-seo.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@sbrv_retina\" \/>\n<meta name=\"twitter:label1\" content=\"Est. tempo de leitura\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/sbrv.org\\\/paciente\\\/doencas-retina\\\/tratamento-dmri-neovascular\\\/\",\"url\":\"https:\\\/\\\/sbrv.org\\\/paciente\\\/doencas-retina\\\/tratamento-dmri-neovascular\\\/\",\"name\":\"Tratamento da DMRI Neovascular: O que \u00e9, Sintomas, Diagn\u00f3stico e Tratamentos | SBRV - SBRV - \u00c1rea do Paciente\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/sbrv.org\\\/paciente\\\/#website\"},\"datePublished\":\"2025-05-05T16:22:02+00:00\",\"dateModified\":\"2025-05-05T18:21:12+00:00\",\"description\":\"Conhe\u00e7a as op\u00e7\u00f5es de tratamento para DMRI neovascular (\u00famida) e como proteger sua vis\u00e3o. Informa\u00e7\u00e3o confi\u00e1vel da SBRV para pacientes e familiares.\u201d\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/sbrv.org\\\/paciente\\\/doencas-retina\\\/tratamento-dmri-neovascular\\\/#breadcrumb\"},\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/sbrv.org\\\/paciente\\\/doencas-retina\\\/tratamento-dmri-neovascular\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/sbrv.org\\\/paciente\\\/doencas-retina\\\/tratamento-dmri-neovascular\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/sbrv.org\\\/paciente\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Gloss\u00e1rio de Doen\u00e7as\",\"item\":\"https:\\\/\\\/sbrv.org\\\/paciente\\\/doencas-retina\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Tratamento da DMRI Neovascular: O que \u00e9, Sintomas, Diagn\u00f3stico e Tratamentos | SBRV\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/sbrv.org\\\/paciente\\\/#website\",\"url\":\"https:\\\/\\\/sbrv.org\\\/paciente\\\/\",\"name\":\"SBRV - Sociedade Brasileira de Retina e Vitreo - \u00c1rea do Paciente\",\"description\":\"Portal da Sociedade Brasileira de Retina e Vitreo\",\"publisher\":{\"@id\":\"https:\\\/\\\/sbrv.org\\\/paciente\\\/#organization\"},\"alternateName\":\"SBRV\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/sbrv.org\\\/paciente\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-BR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/sbrv.org\\\/paciente\\\/#organization\",\"name\":\"SBRV - Sociedade Brasileira de Retina e Vitreo\",\"alternateName\":\"SBRV\",\"url\":\"https:\\\/\\\/sbrv.org\\\/paciente\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/sbrv.org\\\/paciente\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/sbrv.org\\\/paciente\\\/wp-content\\\/uploads\\\/sites\\\/3\\\/2024\\\/12\\\/thumbnail-default-1.png\",\"contentUrl\":\"https:\\\/\\\/sbrv.org\\\/paciente\\\/wp-content\\\/uploads\\\/sites\\\/3\\\/2024\\\/12\\\/thumbnail-default-1.png\",\"width\":600,\"height\":400,\"caption\":\"SBRV - Sociedade Brasileira de Retina e Vitreo\"},\"image\":{\"@id\":\"https:\\\/\\\/sbrv.org\\\/paciente\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/pt-br.facebook.com\\\/sbrv.retina\",\"https:\\\/\\\/x.com\\\/sbrv_retina\",\"https:\\\/\\\/www.instagram.com\\\/retina.sbrv\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Tratamento da DMRI Neovascular: O que \u00e9, Sintomas, Diagn\u00f3stico e Tratamentos | SBRV - SBRV - \u00c1rea do Paciente","description":"Conhe\u00e7a as op\u00e7\u00f5es de tratamento para DMRI neovascular (\u00famida) e como proteger sua vis\u00e3o. Informa\u00e7\u00e3o confi\u00e1vel da SBRV para pacientes e familiares.\u201d","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/sbrv.org\/paciente\/doencas-retina\/tratamento-dmri-neovascular\/","og_locale":"pt_BR","og_type":"article","og_title":"Tratamento da DMRI Neovascular: O que \u00e9, Sintomas, Diagn\u00f3stico e Tratamentos | SBRV - SBRV - \u00c1rea do Paciente","og_description":"Conhe\u00e7a as op\u00e7\u00f5es de tratamento para DMRI neovascular (\u00famida) e como proteger sua vis\u00e3o. Informa\u00e7\u00e3o confi\u00e1vel da SBRV para pacientes e familiares.\u201d","og_url":"https:\/\/sbrv.org\/paciente\/doencas-retina\/tratamento-dmri-neovascular\/","og_site_name":"SBRV - \u00c1rea do Paciente","article_publisher":"https:\/\/pt-br.facebook.com\/sbrv.retina","article_modified_time":"2025-05-05T18:21:12+00:00","og_image":[{"width":1200,"height":675,"url":"https:\/\/sbrv.org\/paciente\/wp-content\/uploads\/sites\/3\/2024\/12\/imagem-yoast-seo.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_site":"@sbrv_retina","twitter_misc":{"Est. tempo de leitura":"4 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/sbrv.org\/paciente\/doencas-retina\/tratamento-dmri-neovascular\/","url":"https:\/\/sbrv.org\/paciente\/doencas-retina\/tratamento-dmri-neovascular\/","name":"Tratamento da DMRI Neovascular: O que \u00e9, Sintomas, Diagn\u00f3stico e Tratamentos | SBRV - SBRV - \u00c1rea do Paciente","isPartOf":{"@id":"https:\/\/sbrv.org\/paciente\/#website"},"datePublished":"2025-05-05T16:22:02+00:00","dateModified":"2025-05-05T18:21:12+00:00","description":"Conhe\u00e7a as op\u00e7\u00f5es de tratamento para DMRI neovascular (\u00famida) e como proteger sua vis\u00e3o. Informa\u00e7\u00e3o confi\u00e1vel da SBRV para pacientes e familiares.\u201d","breadcrumb":{"@id":"https:\/\/sbrv.org\/paciente\/doencas-retina\/tratamento-dmri-neovascular\/#breadcrumb"},"inLanguage":"pt-BR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/sbrv.org\/paciente\/doencas-retina\/tratamento-dmri-neovascular\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/sbrv.org\/paciente\/doencas-retina\/tratamento-dmri-neovascular\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/sbrv.org\/paciente\/"},{"@type":"ListItem","position":2,"name":"Gloss\u00e1rio de Doen\u00e7as","item":"https:\/\/sbrv.org\/paciente\/doencas-retina\/"},{"@type":"ListItem","position":3,"name":"Tratamento da DMRI Neovascular: O que \u00e9, Sintomas, Diagn\u00f3stico e Tratamentos | SBRV"}]},{"@type":"WebSite","@id":"https:\/\/sbrv.org\/paciente\/#website","url":"https:\/\/sbrv.org\/paciente\/","name":"SBRV - Sociedade Brasileira de Retina e Vitreo - \u00c1rea do Paciente","description":"Portal da Sociedade Brasileira de Retina e Vitreo","publisher":{"@id":"https:\/\/sbrv.org\/paciente\/#organization"},"alternateName":"SBRV","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/sbrv.org\/paciente\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-BR"},{"@type":"Organization","@id":"https:\/\/sbrv.org\/paciente\/#organization","name":"SBRV - Sociedade Brasileira de Retina e Vitreo","alternateName":"SBRV","url":"https:\/\/sbrv.org\/paciente\/","logo":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/sbrv.org\/paciente\/#\/schema\/logo\/image\/","url":"https:\/\/sbrv.org\/paciente\/wp-content\/uploads\/sites\/3\/2024\/12\/thumbnail-default-1.png","contentUrl":"https:\/\/sbrv.org\/paciente\/wp-content\/uploads\/sites\/3\/2024\/12\/thumbnail-default-1.png","width":600,"height":400,"caption":"SBRV - Sociedade Brasileira de Retina e Vitreo"},"image":{"@id":"https:\/\/sbrv.org\/paciente\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/pt-br.facebook.com\/sbrv.retina","https:\/\/x.com\/sbrv_retina","https:\/\/www.instagram.com\/retina.sbrv\/"]}]}},"_links":{"self":[{"href":"https:\/\/sbrv.org\/paciente\/wp-json\/wp\/v2\/doenca\/5115","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/sbrv.org\/paciente\/wp-json\/wp\/v2\/doenca"}],"about":[{"href":"https:\/\/sbrv.org\/paciente\/wp-json\/wp\/v2\/types\/doenca"}],"wp:attachment":[{"href":"https:\/\/sbrv.org\/paciente\/wp-json\/wp\/v2\/media?parent=5115"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}